Provided by Tiger Trade Technology Pte. Ltd.

Savara Inc

5.30
+0.14002.71%
Post-market: 5.300.00000.00%19:34 EST
Volume:1.99M
Turnover:10.51M
Market Cap:1.08B
PE:-9.91
High:5.50
Open:5.33
Low:5.13
Close:5.16
52wk High:7.01
52wk Low:1.89
Shares:203.47M
Float Shares:115.00M
Volume Ratio:1.54
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5350
EPS(LYR):-0.4838
ROE:-78.74%
ROA:-39.67%
PB:11.43
PE(LYR):-10.96

Loading ...

Savara Inc. nimmt an bevorstehenden Investor Healthcare Conferences teil

Reuters
·
Feb 05

Savara Inc. Highlights Leadership Team and Progress on MOLBREEVI for Autoimmune PAP in New Presentation

Reuters
·
Jan 29

Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI

Reuters
·
Jan 28

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of Molbreevi*

THOMSON REUTERS
·
Jan 27

Assessing Savara (SVRA) Valuation As Legal Scrutiny Over MOLBREEVI Disclosures Intensifies

Simply Wall St.
·
Jan 26

DIARY-India economic, corporate events on January 20

Reuters
·
Jan 20

Savara Grants Stock Options and RSUs to New Employees

Reuters
·
Jan 17

What Savara (SVRA)'s Exclusive PANTHERx MOLBREEVI Distribution Deal Means For Shareholders

Simply Wall St.
·
Jan 17

Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential

TIPRANKS
·
Jan 10

Savara Submits MOLBREEVI BLA to FDA for Autoimmune PAP Treatment

Reuters
·
Jan 09

Savara Inc : H.c. Wainwright Raises Target Price to $10

THOMSON REUTERS
·
Dec 23, 2025

How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win

Simply Wall St.
·
Dec 23, 2025

Savara Resubmits MOLBREEVI BLA to FDA and Requests Priority Review

Reuters
·
Dec 22, 2025

Savara Resubmits the Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

THOMSON REUTERS
·
Dec 22, 2025

Savara Inc. : Wells Fargo Raises Target Price to $9 From $7

THOMSON REUTERS
·
Dec 18, 2025

Savara Inc. Announces EPO Intention to Grant Patent for Liquid Formulation of MOLBREEVI

Reuters
·
Dec 11, 2025

Savara Announces European Patent Office (Epo) Intends to Grant a Patent for the Liquid Formulation of Molbreevi*

THOMSON REUTERS
·
Dec 11, 2025

Savara Inc. Unveils New Therapies Targeting Rare Respiratory Diseases

Reuters
·
Dec 02, 2025

Savara Inc. and PARI Granted European Patent Covering MOLBREEVI and eFlow Nebulizer Combination

Reuters
·
Dec 02, 2025

BUZZ-India's Mastek rises on report of promoters considering stake sale at premium

Reuters
·
Dec 02, 2025